Efficacy, Immunogenicity, and Safety Study of Clostridium Difficile Toxoid Vaccine in Subjects at Risk for C. Difficile Infection

Trial Profile

Efficacy, Immunogenicity, and Safety Study of Clostridium Difficile Toxoid Vaccine in Subjects at Risk for C. Difficile Infection

Recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Oct 2017

At a glance

  • Drugs Clostridium difficile vaccine (Primary)
  • Indications Clostridium infections
  • Focus Registrational; Therapeutic Use
  • Acronyms Cdiffense
  • Sponsors sanofi pasteur
  • Most Recent Events

    • 11 May 2017 Planned End Date changed from 1 Dec 2017 to 1 Oct 2019.
    • 11 May 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Oct 2019.
    • 11 May 2017 Status changed from active, no longer recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top